

Attorney Docket No.: 320727.00201
Customer No. 27160

U.S. Patent Application No.
10/620,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John W. LUDLOW *et al.* : Group Art Unit: 1632
Application No.: 10/620,433 : Examiner: Not Yet Assigned
Filed: July 17, 2003 : Confirmation No.: Not Yet Assigned
For: METHOD FOR OBTAINING Viable : Atty. Dkt. No.: 320727.00201
HUMAN CELLS, INCLUDING
HEPATIC STEM/PROGENITOR CELLS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 2, 2004

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Forms PTO/SB/08A and PTO/SB/08B. In accordance with current practice, copies of any listed U.S. Patent Documents are not being provided.

FORMAL MATTERS

In accordance with 37 C.F.R. § 1.97(b)(3), since a first Official Action on the merits of the subject application has not yet been issued, neither a certificate, petition nor payment of a fee is believed to be required for this Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any fee which may be required in connection with this paper to Deposit Account No. 50-1710.

Attorney Docket No.: 320727.00201
Customer No. 27160

U.S. Patent Application No.
10/620,433

CONCLUSION

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned indicating that such information has been considered.

Applicant's undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 625-3500. All correspondence should continue to be directed to our address given below.

Respectfully submitted,



Gilberto M. Villacorta, PH.D.
Registration No. 34,038
Sunit Talapatra, PH.D.
Registration No. 54,482

Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, Illinois 60661-3963
(202) 625-3500

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	10/620,433
Filing Date	July 17, 2003
First Named Inventor	John W. LUDLOW
Art Unit	1632
Examiner Name	Not Yet Assigned

Nov 02 2004

2000

TRADE MARK

WAGNER

THE BOSTONIAN

Columns, Lines, Where Messages or Relevant

Messages of Relevance That Appear

—
—
—

1000 J. Neurosci., November 1, 2006 • 26(44):9992–10003

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Joe Worrell

Date
Considered

4/24/06

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known	
				Application Number	10/620,433
				Filing Date	July 17, 2003
				First Named Inventor	John W. LUDLOW
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	2	of	4	Attorney Docket Number	320727.00201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GW	6	Kubota H and Reid LM. 2000, "Clonogenic hepatoblasts, common precursors for hepatocytic and biliary lineages, are lacking classical major histocompatibility complex class I antigen", Proceedings of the National Academy of Sciences (USA) 97: 12132-12137.	✓
	7	Strom SC, Chowdhury JR, and Fox IJ. 1999, "Hepatocyte transplantation for the treatment of human disease (Review)", Seminars in Liver Disease 19: 39-48.	✓
	8	Fox et al., I. J., 1998, "Treatment of the Crigler-Najjar Syndrome Type I with hepatocyte transplantation," New England Journal of Medicine, 338:1422-1426.	✓
	9	Gupta et al., 1992, "Hepatocyte Transplantation: Development of New Systems for Liver Repopulation and Gene Therapy", Seminars in Liver Disease 12, 321.	✓
	10	Wilson et al., 1990, "Temporary Amelioration of Hyperlipidemia in Low Density Lipoprotein Receptor-Deficient Rabbits Transplanted with Genetically Modified Hepatocytes", Proceedings of the National Academy of Sciences USA 87:8437.	✓
	11	Wu et al., 1991, "Receptor-Mediated Gene Delivery In Vivo", Journal of Biological Chemistry 266:14338.	✓
	12	Logan & Shenk, 1984, "Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection", Proc. Natl. Acad. Sci. USA 81:3655-3659.	✓
	13	Mackett et al., 1982, "Vaccinia Virus: A Selectable Eukaryotic Cloning and Expression Vector", Proc. Natl. Acad. Sci. USA 79:7415-7419.	✓
	14	Mackett et al., 1984, "General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes", J. Virol. 49:857-864.	✓
	15	Panicali et al., 1982, "Construction of Poxviruses as Cloning Vectors: Insertion of the Thymidine Kinase Gene from Herpes Simplex Virus into the DNA of Infectious Vaccinia Virus", Proc. Natl. Acad. Sci. USA 79:4927-4931.	✓

Examiner Signature		Date Considered	6/24/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4


Application Number	10/620,433
Filing Date	July 17, 2003
First Named Inventor	John W. LUDLOW
Art Unit	1632
Examiner Name	Not Yet Assigned

Attorney Docket Number

320727.00201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	16	Barber, et al., 1981, "Bovine Papilloma Virus Deoxyribonucleic Acid: a Novel Eucaryotic Cloning Vector", Mol. Cell. Biol. 1:486.	✓
	17	Cone & Mulligan, 1984, "High-Efficiency Gene Transfer into Mammalian Cells: Generation of Helper-Free Recombinant Retrovirus with Broad Mammalian Host Range", Proc. Natl. Acad. Sci. USA 81:6349-6353.	✓
	18	Wigler, et al., 1977, "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell 11:223.	✓
	19	Szybalska & Szybalski, 1962, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", Proc. Natl. Acad. Sci. USA 48:2026.	✓
	20	Lowy, et al., 1980, "Isolation of Transforming DNA: Cloning the Hamster aprt Gene", Cell 22:817.	✓
	21	Wigler, et al., 1980, "Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene", Proc. Natl. Acad. Sci. USA 77:3567.	✓
	22	O'Hare, et al., 1981, "Transformation of Mouse Fibroblasts to Methotrexate Resistance by a Recombinant Plasmid Expressing a Prokaryotic Dihydrofolate Reductase", Proc. Natl. Acad. Sci. USA 78:1527.	✓
	23	Mulligan & Berg, 1981, "Selection for Animal Cells that Express the Escherichia coli Gene Coding for Xanthine-guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. USA 78:2072.	✓
	24	Colberre-Garapin, et al., 1981, "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", J. Mol. Biol. 150:1.	✓
	25	Santerre, et al., 1984, "Expression of Prokaryotic Genes for Hygromycin B and G418 Resistance as Dominant-Selection Markers in Mouse L Cells", Gene 30:147.	✓

Examiner Signature		Date Considered	6/24/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

4

Application Number	10/620,433
Filing Date	July 17, 2003
First Named Inventor	John W. LUDLOW
Art Unit	1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	320727.00201

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
700	26	Hartman & Mulligan, 1988, "Two Dominant-acting Selectable Markers for Gene Transfer Studies in Mammalian Cells", Proc. Natl. Acad. Sci. USA 85:8047.	✓
	27	Naldini et al., 1996, "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science 272:263-267.	✓
	28	Brister et al., 2002, "Hepatitis C Virus Non-Structural Protein 3-Specific Cellular Immune Responses Following Single or Combined Immunization with DNA or Recombinant Semliki Forest Virus Particles", J. Gen. Virol. 83 (Pt. 2):369-381.	✓

Examiner
SignatureDate
Considered

6/24/08

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
 Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.